Related references
Note: Only part of the references are listed.A systematic review of neuroimaging for cerebral palsy
Steven J. Korzeniewski et al.
JOURNAL OF CHILD NEUROLOGY (2008)
Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease
Mario A. Cabrera-Salazar et al.
MOLECULAR THERAPY (2007)
Neurological deterioration in late infantile neuronal ceroid lipofuscinosis
S. Worgall et al.
NEUROLOGY (2007)
Assessing disease severity in late infantile neuronal ceroid lipofuscinosis using quantitative MR diffusion-weighted imaging
J. P. Dyke et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2007)
Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector
Dolan Sondhi et al.
MOLECULAR THERAPY (2007)
CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis
MA Griffey et al.
MOLECULAR THERAPY (2006)
Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain
CN Cearley et al.
MOLECULAR THERAPY (2006)
Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis
MA Passini et al.
JOURNAL OF NEUROSCIENCE (2006)
Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or-2 serotypes for widespread gene delivery to the neonatal mouse brain
MLD Broekman et al.
NEUROSCIENCE (2006)
Safety of direct administration of AAV2CUhCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates
NR Hackett et al.
HUMAN GENE THERAPY (2005)
AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL
D Sondhi et al.
GENE THERAPY (2005)
AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease
MA Passini et al.
MOLECULAR THERAPY (2005)
Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders
LM Arkin et al.
HUMAN GENE THERAPY (2005)
Sustained, high-level expression of human acid alpha-glucosidase and correction of glycogen storage disease type II (GSD II) with an adeno-associated virus 8 (AAV2/8) vector containing a liver-specific promoter
LM Franco et al.
MOLECULAR THERAPY (2004)
Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum
A Cressant et al.
JOURNAL OF NEUROSCIENCE (2004)
Adeno-associated virus vector-mediated transduction in the cat brain
CH Vite et al.
GENE THERAPY (2003)
Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system
RE Haskell et al.
GENE THERAPY (2003)
Late infantile neuronal ceroid lipofuscinosis:: Quantitative description of the clinical course in patients with CLN2 mutations
R Steinfeld et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Gene therapy of Canavan disease:: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain
C Janson et al.
HUMAN GENE THERAPY (2002)
Feasibility of gene therapy for late neuronal ceroid lipofuscinosis
D Sondhi et al.
ARCHIVES OF NEUROLOGY (2001)
Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII (vol 3, pg 351, 2001)
A Frisella et al.
MOLECULAR THERAPY (2001)
Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII
WA Frisella et al.
MOLECULAR THERAPY (2001)
Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors
A Bosch et al.
MOLECULAR THERAPY (2000)
Share Paper
